Minimal Residual Disease Testing Market To Reach $7.1 Billion By 2033

Minimal Residue Disease Testing Market Growth & Trends

The global minimal residual disease testing market size is estimated to reach USD 7.1 billion by 2033, registering a CAGR of 13.2% from 2026 to 2033, according to a new report by Grand View Research, Inc. The adoption of MRD testing as a novel diagnostic and prognostic assay facilitates robust moderation of treatment regimes to treat all kinds of hematological malignancies. Measurement of therapeutic outcomes is critical for the successful adoption of a given cancer therapeutic regime.

MRD generates important molecular information to better understand the cancer conditions and ultimately work towards leveraging treatment outcomes. Therefore, MRD testing is increasingly used as an end-point analysis step in numerous clinical trial studies for oncology-based research and also effectively records the variations in outcomes due to individual genetic characteristics. For instance, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the assessment of residual cancer cells after treatment with GSK’s hematology therapeutics.

Surgical removal of tumors with other associative therapies does not essentially mean, that the cancerous cells are removed completely. Traces of cancer can remain in the body parts and bloodstream. The diagnosis of such residual cells is crucial for deciding upon the need for further rounds of chemotherapy and radiation. Researchers are devising non-invasive tests to effectively detect MRD. For instance, in February 2022, a blood test from C2i Genomics quantified the residual cancer cells after surgical oncology procedures. The C2inform test also achieved the CE mark clearance and is offered as a ‘software-as-a-medical-device’ MRD test in Europe.

Cancer therapeutics are effectively moderated to avoid a residue of tumorous cells using the relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies are driving the need for consideration of individual genetic characteristics for effective treatment. For instance, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic for increasing access to MRD monitoring in blood cancers. Moreover, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand the outcomes of personalized cancer care by integrating the NeXT tumor profiling (by Personalis) and the personalized ctDNA platform Signatera’s diagnostic products (by Natera, Inc.,) for effectively designing the treatment monitoring regime and assessment of MRD.

 Request a free sample copy or view the report summary: Minimal Residual Disease Testing Market Report

Minimal Residue Disease Testing Market Report Highlights

• The flow cytometry segment accounted for largest revenue share of 35.9% in 2025 driven by driven by its rapid and precise detection capabilities. This technology identifies abnormal cells by analyzing multiple cellular markers simultaneously, allowing clinicians to detect residual cancer cells even at very low levels.

• Hematological malignancy cancer dominated the market with revenue of 56.8% in 2025 and is the fastest-growing segment driven by high prevalence of blood cancers such as leukemia, lymphoma, and multiple myeloma.

• The hospitals and specialty clinics segment accounted the largest share of 50.2% in 2025 due to their advanced diagnostic capabilities and access to specialized healthcare professionals. These facilities are equipped with cutting-edge technologies like flow cytometry, PCR, and next-generation sequencing, enabling precise MRD detection.

• North America dominated the minimal residual disease testing market in 2025, which is attributed to the growing prevalence of hematological malignancies in the region aided by a well-developed reimbursement landscape.

Minimal Residue Disease Testing Market Segmentation

Grand View Research has segmented the global minimal residual testing market report based on cancer type, technology, end use, and region:

Minimal Residue Disease Testing Technology Outlook (Revenue, USD Million, 2021 - 2033)

• Flow Cytometry

• Polymerase Chain Reaction (PCR)

• Next Generation Sequencing (NGS)

• Others

Minimal Residue Disease Testing Cancer Outlook (Revenue, USD Million, 2021 - 2033)

• Hematological Malignancy

  • Leukemia

  • Lymphoma

• Solid Tumors

Minimal Residue Disease Testing End use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospitals and Specialty Clinics

• Diagnostic Laboratories

• Academic and Research Institutes

• Others

Minimal Residue Disease Testing Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Spain

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Minimal Residue Disease Testing Market

• Exact Sciences Corporation

• GRAIL, LLC

• Veracyte, Inc.

• Natera, Inc.

• Guardant Health

• F. Hoffmann-La Roche Ltd

• FOUNDATION MEDICINE, INC.

• QIAGEN

• mdxhealth.

• Bio-Techne.